Skip to main content

Articles

Page 9 of 9

  1. The identification of disease markers in human body fluids requires an extensive and thorough analysis of its protein constituents. In the present study, we have extended our analysis of the human cerebrospina...

    Authors: Giuseppina Maccarrone, Isabel Birg, Eva Malisch, Marcus C. Rosenhagen, Claudia Ditzen, John A. Chakel, Friedrich Mandel, Andreas Reimann, Can-Carlo Doertbudak, Katrin Haegler, Florian Holsboer and Christoph W. Turck

    Citation: Clinical Proteomics 2004 1:13104333

    Content type: Original Article

    Published on:

  2. The evaluation of clinical tumor tissues is a valuable approach to discovering novel drug targets because of the direct relevance of human samples. We used activity-based proteomic profiling (ABPP) to study th...

    Authors: Melissa C. Zhang, Jiangyue Wu, Kristin G. Ardlie and Emme C. K. Lin

    Citation: Clinical Proteomics 2004 1:13104301

    Content type: Original Article

    Published on:

  3. In this study, proteomics was used to explore the antigenic proteins that are involved in cross-reactivity during serodiagnosis between Neospora caninum (N. caninum) and Toxoplasma gondii (T. gondii). Competitive...

    Authors: Yong-seung Shin, Eung-goo Lee, Gee-wook Shin, Young-rim Kim, Eun-young Lee, Jae-hoon Kim, Hwan Jang, Dae-yong Kim, Yong-hwan Kim, Gon-sup Kim, Myung-deuk Suh and Tae-sung Jung

    Citation: Clinical Proteomics 2004 1:235

    Content type: Original Article

    Published on:

  4. Changes in serum proteins that signal histopathological states, such as cancer, are useful diagnostic and prognostic biomarkers. Unfortunately, the large dynamic concentration range of proteins in serum makes ...

    Authors: King C. Chan, David A. Lucas, Denise Hise, Carl F. Schaefer, Zhen Xiao, George M. Janini, Kenneth H. Buetow, Haleem J. Issaq, Timothy D. Veenstra and Thomas P. Conrads

    Citation: Clinical Proteomics 2004 1:12101

    Content type: Serum/Plasma Proteome

    Published on:

  5. In order to evaluate the critical components of the process necessary to preserve clinical plasma samples collected at research sites for proteomic analysis, various collection and preservation protocols with ...

    Authors: Jeffrey D. Hulmes, Deidra Bethea, Keith Ho, Shu-Pang Huang, Deborah L. Ricci, Gregory J. Opiteck and Stanley A. Hefta

    Citation: Clinical Proteomics 2004 1:21117

    Content type: Serum/Plasma Proteome

    Published on:

  6. Many protein functions are conferred by posttranslational modifications, which allow proteins to perform specific cellular tasks. Protein microarrays enable specific detection of posttranslational modification...

    Authors: Virginia Espina, Emanuel F. Petricoin III, Lance A. Liotta and David Geho

    Citation: Clinical Proteomics 2004 1:11091

    Content type: Brief Technical Report

    Published on:

  7. Protein microarrays have been recently employed for signal pathway profiling and high-throughput protein expression analysis. Reversephase arrays, where the array consists of immobilized analytes and lysates h...

    Authors: Valerie S. Calvert, Yihui Tang, Vince Boveia, Julie Wulfkuhle, Amy Schutz-Geschwender, D. Michael Olive, Lance A. Liotta and Emanuel F. Petricoin III

    Citation: Clinical Proteomics 2004 1:11081

    Content type: Brief Technical Report

    Published on:

  8. The purpose of this phospho-proteomics study was to demonstrate the broad analysis of cellular protein phosphorylation in cells and tissue as a means to monitor changes in cellular states. As a cancer model, h...

    Authors: David R. Stover, Jennifer Caldwell, Jarrod Marto, Karen Root, Juergan Mestan, Michael Stumm, Olga Ornatsky, Chris Orsi, Nina Radosevic, Linda Liao, Doriano Fabbro and Michael F. Moran

    Citation: Clinical Proteomics 2004 1:11069

    Content type: Molecular Targets

    Published on:

  9. Methotrexate has been a clinical agent used in cancer, immunosuppression, rheumatoid arthritis and other highly proliferative diseases for many years, yet its underlying molecular mechanism of action in these ...

    Authors: Leticia M. Toledo-Sherman, Leroi Desouza, Christopher M. Hosfield, Linda Liao, Kelly Boutillier, Paul Taylor, Shane Climie, Linda McBroom-Cerajewski and Michael F. Moran

    Citation: Clinical Proteomics 2004 1:11045

    Content type: Molecular Targets

    Published on:

  10. Monitoring increased plasma unbound free fatty acid (FFAu) concentrations has been proposed as a biomarker for myocardial ischemia. In the current study, 30 acute coronary syndrome (ACS) patients presenting in th...

    Authors: Fred S. Apple, Alan M. Kleinfeld and Jesse Adams III

    Citation: Clinical Proteomics 2004 1:11041

    Content type: Biomarker Discovery and Profiling

    Published on:

  11. The tissue specificity of creatine kinase (CK-MB) has been shown not to be absolute for the myocardium. Unexplained increases of plasma creatine kinase (CK-MB) occur in patients with skeletal muscle disease, c...

    Authors: Vincent Ricchiuti, Ellen M. Voss, Arthur Ney, Mark Odland and Fred S. Apple

    Citation: Clinical Proteomics 2004 1:11033

    Content type: Biomarker Discovery and Profiling

    Published on:

  12. With increased interest in clinical proteomics—the comparative investigation of differential protein expression patterns for use in the diagnostic and prognostic assessment of disease states—the demand for tec...

    Authors: Urban A. Kiernan, Dobrin Nedelkov, Kemmons A. Tubbs, Eric E. Niederkofler and Randall W. Nelson

    Citation: Clinical Proteomics 2004 1:11007

    Content type: Serum/Plasma Proteome

    Published on:

Annual Journal Metrics